(Total Views: 192)
Posted On: 10/12/2017 10:10:32 AM
Post# of 72446
This stock went up 56% on positive Phase III data that is FAR WORSE than the data we have for Brilacidin-UP so far. This stuff has only 36.5% efficacy, yet they say that's enough to make it approvable:
https://endpts.com/ardelyx-steps-up-with-a-be...%20Synergy
https://endpts.com/ardelyx-steps-up-with-a-be...%20Synergy
(3)
(0)
